Food and Drug Administration (FDA) Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Is there a role for the laboratory monitoring in the management of specific antidotes of direct oral anticoagulants?
Given the growing number of patients receiving direct oral anticoagulant (DOAC), patients requiring rapid neutralization is also increasing in case of major bleedings or urgent surgery/procedures. Idarucizumab is commercialized as a specific antidote to dabigatran while andexanet alfa has gained the Food and Drug Administration and the European Medicines Agency approval as an oral anti-factor Xa inhibitors antidote. Other antidotes or hemostatic agents are still under preclinical or clinical development, the most advanced being ciraparantag. (Source: Thrombosis Research)
Source: Thrombosis Research - April 9, 2024 Category: Hematology Authors: Nicolas Gendron, Paul Billoir, Virginie Siguret, V éronique Le Cam-Duchez, Valérie Proulle, Laurent Macchi, Elodie Boissier, Christine Mouton, Emmanuel De Maistre, Isabelle Gouin-Thibault, Georges Jourdi, French Society on Thrombosis and Haemostasis Source Type: research

SPOOC (Sensor for Periodic Observation of Choline): An Integrated Lab ‐on‐a‐Spoon Platform for At‐Home Quantification of Choline in Infant Formula
SPOOC, a fast, accurate, and wireless device, quantifies choline in infants' formulas in home settings. It utilizes laser-induced graphene as a platform for choline potentiometric detection and features a detachable potentiometric device that wirelessly transmits data to nearby smartphones. This device assists parents in ensuring infants receive sufficient choline, promoting better neural and muscular health. AbstractCholine is an essential micronutrient for infants' brain development and health. To ensure that infants receive the needed daily dose of choline, the U.S. Food and Drug Administration (FDA) has set requirement...
Source: Small - April 8, 2024 Category: Nanotechnology Authors: Abdulrahman Al ‐Shami, Farbod Amirghasemi, Ali Soleimani, Sina Khazaee Nejad, Victor Ong, Alara Berkmen, Alar Ainla, Maral P.S. Mousavi Tags: Research Article Source Type: research

Mavacamten: A Review of a Novel Therapeutic Approach for Hypertrophic Cardiomyopathy
Cardiovasc Hematol Agents Med Chem. 2024 Apr 5. doi: 10.2174/0118715257283752240325082733. Online ahead of print.ABSTRACTHypertrophic Cardiomyopathy (HCM) is a heart disease that can cause left ventricular hypertrophy, arrhythmias, heart failure, and sudden cardiac death. Currently, pharmacological treatment is limited and ineffective. Mavacamten (CamzyosTM) is a cardiac myosin inhibitor developed as a therapeutic option to reduce myocardial contractility and restoration of myocardial function. The Food and Drug Administration (FDA) approved the use of Mavacamten in 2022 for HCM symptoms. Clinical studies have proven that ...
Source: Cardiovascular and Hematological Agents in Medicinal Chemistry - April 8, 2024 Category: Cardiology Authors: Ayesha Abdul Qadir Memon Areeba Shamim Sanoober Mirza Muhammad Osama Iyad Naeem Muhammad Calvin R Wei Source Type: research

Neural tissue tolerance to synthetic dural mater graft implantation in a rabbit durotomy model
This study evaluated the safety of ArtiFascia, a synthetic dura mater graft composed of poly(l-lactic-co-caprolactone acid) and poly(d-lactic-co-caprolactone acid), in a rabbit durotomy model. Previously, ArtiFascia demonstrated positive local tolerance and biodegradability in a 12-month preclinical trial. Here, specialized stains were used to evaluate potential brain damage associated with ArtiFascia use. Histochemical and immunohistochemical assessments included Luxol Fast Blue, cresyl Violet, Masson's Trichrome, neuronal nuclei,, Glial Fibrillary Acidic Protein, and ionized calcium-binding adaptor molecule 1 stains. The...
Source: Journal of Toxicologic Pathology - April 8, 2024 Category: Toxicology Authors: Yuval Ramot Noam Kronfeld Michal Steiner Nora Nseir Manassa Amir Bahar Abraham Nyska Source Type: research